{"Patient ID": 0.0, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Apo A1\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Apo B\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Baseline blood draw at least 8 hours after last meal\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\CRP(Denka)\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Creatinine\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Diastolic blood pressure\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Fibrinogen\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\HDL cholesterol in mg/dl at baseline\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\HbA1c\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Homocysteine\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\ICAM\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\LDL cholesterol in mg/dl at baseline, direct measure\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Lp(a)\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Principal Components\\Principal component 10\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Principal Components\\Principal component 1\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Principal Components\\Principal component 2\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Principal Components\\Principal component 3\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Principal Components\\Principal component 4\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Principal Components\\Principal component 5\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Principal Components\\Principal component 6\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Principal Components\\Principal component 7\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Principal Components\\Principal component 8\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Principal Components\\Principal component 9\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Systolic blood pressure\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Total cholesterol at baseline\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Triglycerides in mg/dl at baseline\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Lifestyle and Environment\\Alcohol use\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Lifestyle and Environment\\Cholesterol lowering medication at baseline\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Lifestyle and Environment\\Exercise\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Lifestyle and Environment\\Smoking status\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Physical Observations\\Age at AF diagnosis\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Physical Observations\\Age at enrollment\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Physical Observations\\Age at menarche\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Physical Observations\\Age at menopause\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Physical Observations\\Body mass index\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Physical Observations\\Diabetes at baseline\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Physical Observations\\Height\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Physical Observations\\Metabolic syndrome\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Physical Observations\\Uterine fibroids\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Physical Observations\\Waist/hip ratio\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Physical Observations\\Weight\\": NaN, "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Sample Attributes\\TOPMed Phase\\": NaN}